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Arginase (ARG) represents an important evolutionarily conserved enzyme that is expressed
by multiple cell types in the skin. Arg acts as the mediator of the last step of the urea cycle,
thus providing protection against excessive ammonia under homeostatic conditions through
the production of L-ornithine and urea. L-ornithine represents the intersection point between
the ARG-dependent pathways and the urea cycle, therefore contributing to cell
detoxification, proliferation and collagen production. The ARG pathways help balance
pro- and anti-inflammatory responses in the context of wound healing. However, local
and systemic dysfunctionalities of the ARG pathways have been shown to contribute to the
hindrance of the healing process and the occurrence of chronic wounds. This review
discusses the functions of ARG in macrophages and fibroblasts while detailing the
deleterious implications of a malfunctioning ARG enzyme in chronic skin conditions such
as leg ulcers. The review also highlights how ARG links with the microbiota and how this
impacts on infected chronic wounds. Lastly, the review depicts chronic wound treatments
targeting the ARG pathway, alongside future diagnosis and treatment perspectives.
Keywords: wound healing, arginase (ARG), chronic wounds, polyamines, diabetic foot ulcers (DFU), venous leg
ulcers (VLU)
INTRODUCTION
The skin represents a multifaceted organ with a complex architecture and biology. Due to the vast
array of skin components and functions, it follows that cutaneous wound healing has to be a well-
coordinated cascade of intricate events to ensure a re-establishment of protection against
environmental hazards and infections.
Over the last decades, there has been an increasing interest in the Arginase (ARG) pathways and
their link to the proper progression through the wound healing cascade. ARG has been shown to
have ample physiological implications, due to being the nexus of upstream signalling events as well as
downstream metabolism of polyamines and proline (Caldwell et al., 2018). ARG dysfunction has
been extensively linked to cardiovascular and neuropathic conditions (Gao et al., 2007; Pernow and
Jung 2013; Caldwell et al., 2015). More and more studies are also highlighting a link between this
enzyme and impaired wound healing (Jude et al., 1999; Abd-El-Aleem et al., 2000; Campbell et al.,
2013; Abd El-Aleem et al., 2019). However, the implications of a malfunctioning ARG enzyme in
wound chronicity are not well-understood.
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This review aims to give an overview of ARG activity and the
current understanding of how it relates to wound healing.
Arginase Pathways Overview
ARG represents an evolutionarily conserved ureohydrolase
enzyme involved in the final step of the urea cycle (Dzik
2014). This manganese (Mn)-containing metalloenzyme
catalyses the conversion of L-arginine into L-ornithine and
urea, thus being crucial for the disposal of toxic nitrogen
resulting from amino acid (AA) and nucleotide metabolism
(Meijer et al., 1990; Wu and Morris 1998).
The expression and activity of the enzyme ARG has been
associated with several intracellular signalling events such as the
activation of Rho kinase, Mitogen-Activated Protein Kinase
(MAPK) and Protein Kinase A (PKA) (Shatanawi et al., 2011;
Chandra et al., 2012). Moreover, multiple wound healing-related
cytokines like Transforming Growth Factorβ (TGFβ),
Interleukin-4 (IL-4), IL-6, IL-8, IL-13 and Tumour Necrosis
Factor α (TNFα) have also been linked to the modulation of
ARG activity, TGFβ being one of the most potent activators of
ARG1 (Gordon 2003; Gao et al., 2007; Chandra et al., 2012). The
Reactive Oxygen Species (ROS) produced early in the wound
microenvironment might also modulate ARG activity, the ARG1
promoter region containing potential redox-sensitive elements
(Kawamoto et al., 1987). ARG1 is also a CCAAT/Enhancer-
Binding Protein-β (C/EBP-β) target gene (Ruffell et al., 2009).
The activity of C/EBP-β is antagonised by Protein phosphatase 6
(Pp6), an epidermis-specific Ser/Thr phosphatase is essential for
skin homeostasis (Lou et al., 2020).
Enzyme Isoforms and their Distribution
ARG has two isoforms ARG1 and ARG2, each one being encoded
by different genes located on separate chromosomes. ARG1 is
localised in the cytosol and, although it is mainly expressed in the
liver and immune cell populations such as alternatively activated
macrophages (AAMs) (Pauleau et al., 2004), it is also found in
multiple cell types involved in the wound healing process
including fibroblasts, keratinocytes and endothelial cells
(Albina et al., 1990; Witte et al., 2002; Kampfer et al., 2003).
Endothelial cells express both ARG isoforms (Buga et al., 1996;
Bachetti et al., 2004), while smooth muscle cells possess ARG1
activity only (Durante et al., 1997). In fibroblasts ARG1 activity is
upregulated by certain growth factors like TGFβ and
haemodynamic forces including cyclic stretch (Durante et al.,
2000).
ARG2 is present in the mitochondria and is highly expressed
in tissues such as the kidneys, brain and retinas (Caldwell et al.,
2018). ARG1 consists of 322 AAs (Dizikes et al., 1986), while
ARG2 comprises 354 AAs (Gotoh et al., 1996). The two isoforms
having a 60% homology in AA residues, whilst the areas critical to
their catalytic function have 100% homology (Vockley et al.,
1996).
GRAPHICAL ABSTRACT | Arginase (ARG) pathways in wound healing. (A) Dysfunctionalities of ARG pathways have been regarded as contributing factors to the
occurrence of chronic wounds such as DFUs or VLUs, the presence of bacterial populations adding a further layer of complexity to the pathophysiology of these
conditions (B) Various treatment options based on the activity of the ARG pathways have been devised, popular choices being amino acid supplementation by both
enteral and parenteral routes as well as enzyme inhibitors, such as the potent drug nor-NOHA. (C) However, ARG pathways-based monotherapies have showed
limited success, highlighting the need to focus on patient comorbidities as well as ARG-expressing cell interactions when devising future chronic wound treatments.
Abbreviations: ARG, arginase; ABH, 2(S)-amino-6-boronohexanoic acid; BEC, S-(2-boronoethyl)-L-cysteine; DFU, Diabetic Foot Ulcer; iNOS, inducible Nitric Oxide
Synthase; nor-NOHA, Nω-hydroxy-nor-arginine; VLU, Venous Leg Ulcer.
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As illustrated in Figure 1, Nitric Oxide Synthase (NOS), the
antagonist of ARG, is an enzyme catalysing the conversion of
L-arginine into L-citrulline and Nitric Oxide (NO)
(Schwentker and Billiar 2003). There are three different
isoforms of NOS with slightly different functions and
cellular localisation, namely neuronal NOS (nNOS or
NOS1), inducible NOS (iNOS or NOS2) and endothelial
NOS (eNOS or NOS3) (Witte and Barbul 2002;
Schwentker and Billiar 2003).
Whilst nNOS and eNOS are discretely expressed in the brain and
blood vessels respectively, iNOS is located in a variety of tissues,
including the skin (Frank et al., 2002; Nieves and Langkamp-Henken
2002; Witte and Barbul 2003). Both eNOS and nNOS represent
Ca2+-dependent isoforms that are constitutively expressed in their
specific tissues (Nathan and Xie 1994), whilst iNOS is Ca2+-
independent and mainly produced in pathological conditions
(Ischiropoulos et al., 1992). This review will mainly focus on the
functions of the iNOS and eNOS isoforms.
L-arginine in ARG and NOS Homeostatic
Push-And-Pull
L-arginine is a dibasic, conditionally non-essential AA derived
from either protein turnover or diet (Figure 1). This AA is
tightly linked to several metabolic pathways involved in the
synthesis of creatine, agmatine, urea, nitric oxide (NO) and
polyamines (Witte and Barbul 2003). Decreased L-arginine
plasma levels are observed in patients with trauma, burn
wounds or those undergoing surgery, this reduction in its
availability being associated with the increased metabolic
demand triggered by the systemic inflammatory responses
(Nijveldt et al., 2000; Ochoa et al., 2001; Yu et al., 2001).
Randomised clinical trials in patients with severe skin burns
highlight the beneficial effects of L-arginine enteral
administration on burn healing, further suggesting a
necessary increase in L-arginine catabolism (Yan et al., 2007).
This increased L-arginine metabolism in the context of skin
wounds is a first clue to the implications of ARG pathway in
wound healing.
L-arginine represents the common substrate that ARG and
NOS compete for (Figure 1). Therefore, under homeostatic
conditions, the activities of these two enzyme systems are
mutually exclusive. Certain regulatory mechanisms account for
further activity control; Nitrite (NO2), the stable metabolite of
NO, suppresses ARG (Hrabak et al., 1996), while the polyamine
spermidine, an ARG downstream metabolite, can suppress NOS
activity (Szabo et al., 1994).
FIGURE 1 | Overview of L-arginine metabolism. Simplified diagram summarising the ARG pathways, together with polyamine and collagen synthesis. The NOS
branch of the ARG pathways is highlighted in green, polyamine production in orange and collagen production in yellow. L-arginine is an AA that can be derived either from
diet or from recycled L-citrulline deriving from glutamate, glutamine or proline. L-arginine can be metabolised by ARG1 during the urea cycle, L-ornithine and urea being
its breakdown products. L-ornithine, in turn, can be the precursor of several molecular events including the synthesis of L-proline via OAT, the synthesis of the
polyamine putrescine via ODC, and the production of L-citrulline via OCT. L-proline represents a key collagen building block. Putrescine, together with its downstream
products spermidine and spermine, make up the reversible polyamine pathway that contributes to cell proliferation. An important rate-limiting enzyme of the polyamine
pathway is AMD1. L-arginine is also a secretagogue for growth hormone (GH), which contributes to cell proliferation via IGF-1-dependent polyamine pathway
enhancement. Finally, L-arginine can be metabolised by NOS, the reaction products being NO and L-citrulline. Enzymes are highlighted in red. Abbreviations: AA, amino
acid; AdoMet, S-Adenosyl methionine; AMD1, AdoMet decarboxylase; ASL, argininosuccinate lyase; ASS, argininosuccinate synthase; dcAdoMet, decarboxylated
AdoMet; GH, growth hormone; IGF-1, insulin-like growth factor 1; MTA, 5′-methylthioadenosine; NO, nitric oxide; NOS, nitric oxide synthase; OAT, ornithine
aminotransferase; OAZ, ornithine decarboxylase antizyme; OCT, ornithine carbamoyl transferase; ODC, ornithine decarboxylase; P5C, L-Δ1-pyrroline-5-carboxylate;
P5CR, P5C reductase; PAO, polyamine oxidase; PRL, prolactin; SM, spermine synthase; SMO, spermine oxidase; SRM, spermidine synthase; SSAT, spermidine ⁄
spermine N1 -acetyltransferase.
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ARG Pathway and Polyamine Production
Due to being a secretagogue for Growth Hormone (GH) (Nieves
and Langkamp-Henken 2002), L-arginine indirectly induces the
secretion of Insulin-like Growth Factor-1 (IGF-1) (Merimee et al.,
1965; Merimee et al., 1967). IGF-1, which is also important for
cell growth, acts, in turn, on Ornithine Decarboxylase (ODC;
Figure 1) which is the first rate-limiting enzyme involved in
polyamine synthesis. ODC decarboxylates L-ornithine into
putrescine (Regunathan and Reis 2000; Witte and Barbul
2003). Putrescine is then sequentially converted into
spermidine and spermine through the addition of an
aminopropyl group from dcAdoMet. dcAdoMet results from
the decarboxylation of AdoMet via Adenosylmethionine
Decarboxylase 1 (AMD1), the second rate-limiting enzyme of
the polyamine pathway (Figure 1) (Casero et al., 2018).
The polyamines are important for cell growth and
proliferation (Langkamp-Henken et al., 1998; Li et al., 2001),
being able to modulate a wide range of cellular functions
including transcription, translation, cytoskeleton assembly and
ion transport (Iarashi and Kashiwagi 2010; Lightfoot and Hall
2014).
ARG, Collagen Production and Fibrosis
Besides polyamines, L-ornithine is also the precursor for proline,
the AA produced through the activity of Ornithine
Aminotransferase (OAT; Figure 1). Proline is one of the main
constituents of collagen and its increased production contributes
to the post-traumatic increase in wound tensile strength,
parenteral administration of L-arginine enhancing wound
hydroxyproline levels in the dorsal skin incisions of both
control and diabetic Lewis rats (Witte and Barbul 2003;
Caldwell et al., 2018). Enhanced collagen production can lead
to connective tissue thickening and subsequent fibrosis, as shown
by studies based on both the activity of proline hydroxylase and
the collagen incorporation rate of radiolabelled proline in skin
tissue explants (Craig 1975; Rockwell et al., 1989). The enzymatic
activity of proline hydroxylase correlates well with the rate of
collagen synthesis, and the activity of this enzyme is markedly
increased in the fibrotic areas of hypertrophic and keloid scars,
when compared to normal scars (Craig 1975), thus putatively
linking an enhanced collagen synthesis to the aetiology of fibrosis.
The collagen synthesis rate was determined to be 3 times higher in
hypertrophic scars and 20 times higher in keloids, when
compared to normal scars (Rockwell et al., 1989). Fibrotic
areas can also be seen in the dermal tissue surrounding
chronic wounds (Abd-El-Aleem et al., 2000; Eming et al., 2014).
Wound healing represents an intricate multifactorial process
whose slight dysregulations can impair its overall success. Recent
studies have implicated the ARG pathway in several wound
healing-related cell types and stages with macrophages being
the most extensively studied (Campbell et al., 2013). However,
given its wide expression in the wound site it is likely that arginase
in cell types such as fibroblasts and keratinocytes will play an
important role in healing and their contribution is less well-
defined but should not be underestimated. Irrespective of the
sources of ARG in the wound it is important to consider the
impact of ARG on would healing. The following sections will
review the involvement of ARG in key stages of wound healing,
while emphasising the current understanding of the link between
the ARG pathways and skin healing impairments.
ARG and iNOS in acute Wound Healing
In acute wounds, iNOS activity predominates in the early
inflammatory stage where the wound microenvironment is
cytotoxic. Infiltrating inflammatory cells such as
macrophages and neutrophils synthesize large amounts of
NO (Lyons et al., 1992). The effects of NO release, including
anti-microbial activity (Granger et al., 1988), vasodilation
(Stuehr et al., 1989), and anti-platelet aggregation activity
(Salvemini et al., 1989), are important for the initial wound
decontamination and debridement.
In the late healing stages, iNOS levels return to normal and
ARG activity predominates (Albina et al., 1990), leading to the
production of proline for collagen, and polyamines which are
essential for cell growth, differentiation and matrix modelling
(Sarhan et al., 1992; Shearer et al., 1997). Intracellular polyamine
levels increase in response to cellular damage, this increase
highlighting their putative role in the proliferative stage of
wound healing (Casero and Pegg 2009; Gao et al., 2013).
Moreover, a change in the putrescine/spermine ratio is
important for epithelial tongue migration and wound re-
epithelialisation via Urokinase-type Plasminogen Activator
(uPA)/uPA receptor (uPAR)-driven actin cytoskeleton
reorganisation (Lim et al., 2018).
Due to the complexity of the wound healing phases, the
variable skin architecture of the outbred human population
and differing microbial residency, impairments of skin-related
molecular/cellular mechanisms can arise, leading to the
occurrence of chronic wounds. The next sections are focused
on the implication of the ARG pathways in the pathophysiology
of chronic skin conditions, including ulcers and infected chronic
wounds. Attention is given to the role that ARG plays in key cells
of the wound healing process such as macrophages and
fibroblasts. Current ARG pathway-based chronic wound
treatments are also described, and future perspectives are
emphasised.
MACROPHAGES, ARG PATHWAY AND
WOUND HEALING
Macrophages represent a crucial immune cell population with
extensive physiological implications, among which is the
regulation of wound healing progression. The importance of
macrophages in the wound microenvironment is going to be
detailed in the next section, emphasis being given to the activity of
the ARG pathway in this cell population.
Macrophages as Master Regulators of
Wound Healing
Whilst macrophages seem to be dispensable in early foetal
wounds (Martin et al., 2003), several murine knockout models
have highlighted the need for macrophages in normal adult
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wound healing (Nagaoka et al., 2000; Peters et al., 2005; Ishida
et al., 2008).
Macrophages persist throughout the entire healing response,
their numbers increasing during the inflammatory stage, peaking
during the tissue formation phase and finally declining during the
maturation step (Martin and Leibovich 2005). The use of
Diphtheria Toxin (DT)-mediated macrophage depletion in
Lysozyme M (LysM) Cre/inducible Diphtheria Toxin receptor
(iDTR) mice at early, mid and late wound repair stages showed
the importance of macrophage involvement throughout the
entire healing process. Inflammatory phase-restricted
macrophage depletion led to impaired granulation tissue
formation and re-epithelialisation, while the mid proliferative
stage-restricted macrophage ablation resulted in severe wound
site haemorrhage (Lucas et al., 2010).
In light of their ubiquity and extensive functions, Lawrence
et al. have described macrophages as the “orchestra leaders” of
adult wound healing (Lawrence and Diegelmann 1994). Critical
to the function of macrophages in the healing process is their
plasticity.
Macrophage Plasticity and ARG Pathway
As far as the implications of macrophage-related L-arginine
metabolism are concerned, the initially high levels of wound
site pro-inflammatory cytokines, such as Interferon γ (IFNγ),
TNFα and IL-1β, stimulate the iNOS-dependent production of
large amounts of NO by pro-inflammatory classically activated
(CAM) or M1 macrophages (Witte and Barbul 2002). NO may
then spontaneously react with O2
−, thus yielding toxic
peroxynitrous acids, peroxynitrite and hydroxyl (OH−) radicals
involved in pathogen killing (Beckman et al., 1990; Radi et al.,
1991; Jude et al., 1999; Goldman 2004). In contrast, macrophage
stimulation via cytokines such as IL-4, IL-10, IL-13 and IL-33
leads to a tissue reparative alternatively activated (AAM) M2
macrophage phenotype (Locati et al., 2013; Wang et al., 2014)
associated with an enhanced ARG1 expression and activity
(Munder et al., 1998; Pauleau et al., 2004). This cytokine-
based phenotype switch highlights the plasticity of these
heterogeneous leukocytes and its dependency on their
surrounding milieu (Modolell et al., 1995; Shapouri-
Moghaddam et al., 2018).
Studies focusing on the dichotomous far ends of the
macrophage phenotypic spectrum, namely CAMs/M1 and
AAMs/M2, have suggested that local macrophage ARG1
activity is vital for proper cutaneous wound healing (Gordon
and Taylor 2005; Mosser and Edwards 2008). Differentiated
macrophages appear to have distinct roles in the healing
process-the activity of iNOS predominating in the early stages
of wound healing in CAMs followed by high ARG activity later in
the healing process in AAMs (Campbell et al., 2013; Krzyszczyk
et al., 2018). Moreover, both the local pharmacological inhibition
of ARG using nor- Nω-hydroxy-L-arginine (nor-NOHA) (Tenu
et al., 1999; Takahashi et al., 2010) and the Tie2-mediated
conditional ablation of ARG1 (El Kasmi et al., 2008) triggered
pronounced delays in wound healing, suggesting a possible link
between chronic wounds, ARG dysfunction and macrophage
phenotypic transition.
This phenotypic transition from a M1 pro-inflammatory to a
M2 anti-inflammatory macrophage was manipulated by Kim
et al. via an exosome-guided reprogramming of cell polarity,
with the purpose of accelerating wound healing. The
subcutaneous administration of high purity M2-exosomes
into the excisional wound edge of 5-week-old male Balb/c
mice led to better wound healing outcomes by means of a
successful M1 to M2 phenotypic switch although only
CD86, iNOS and CD206, ARG1 were used to distinguish
M1 and M2 macrophages respectively and fuller
characterisation was not done (Kim et al., 2019). Even if
promising, the therapeutic viability of this in situ exosome-
based phenotypical transition remains questionable as the
study did not test their effectiveness in animal models with
underlying pathological conditions. Moreover, a challenge
in studying macrophage function includes the usage of
iNOS and ARG1 as markers of M1 vs. M2 phenotypes, as
certain macrophages (such as the alveolar macrophages)
express both markers (Thomas and Mattila 2014). Mouse
age may pose a further difficulty, especially from a
translational perspective, the incidence of wound healing
problems and chronicity increasing with age (Jackson et al.,
2017).
Due to their pervasive role in the wound healing process, it
becomes obvious that macrophage malfunctions are a likely
contributor to the pathophysiology of chronic wound
impairments. The next section will focus on the underlying
causes of skin ulcers while highlighting the implication of
ARG1 and macrophage dysfunction in impaired healing/
chronicity.
ARG1 in Chronic Wounds
Owing to its expression in several cell types involved in wound
healing as well as its ability to influence cell proliferation and
collagen deposition by means of its downstream metabolites
(Caldwell et al., 2018), it can be assumed that ARG might play
a role in the non-healing status of chronic wounds. Ulcers
represent prevalent chronic lesions that arise as a result of
halted progression through the wound healing cascade (Agren
et al., 2000). Given that ARG is involved in wound healing and
skin ulcers represent a sequela of impaired cutaneous healing, the
possible relationship between a malfunctioning ARG pathway
and the underlying aetiology of ulcers is important to consider.
Ulcers represent a major concern from both a clinical and
economic point of view, as the number of patients suffering from
chronic wounds is reaching epidemic proportions (Brem and
Tomic-Canic 2007; Sen et al., 2009; Guest et al., 2018). Moreover,
the aging, multi-morbid population poses a further burden to the
clinical world, the management of ulcers having to cater for both
the systemic conditions such as diabetes as well as the local
wound disorders (Eming et al., 2014). Depending on the
underlying causes, there are several types of ulcers (Eming
et al., 2014). For the purpose of this review, Venous Leg
Ulcers (VLUs) and Diabetic Foot Ulcers (DFU) will be the
main focus. However, it is worth noting that Arterial Ulcers
(AU) and Pressure Ulcers (PU) represent important clinical
challenges as well (Eming et al., 2014).
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VLUs represent a common form of leg ulcers with increased
incidence among the elderly. VLUs are one of the most severe
symptoms of low extremity chronic venous insufficiency (Bergan
et al., 2006; Raju and Neglén 2009). DFUs are regarded as one of
the most common reasons for hospital admission among diabetic
patients (Williams 1985), leading to 50–70% of all non-traumatic
amputations (Boulton 1997; Margolis et al., 2005). Even more
worrying is the anticipation that the prevalence of Type 2
Diabetes Mellitus (T2DM) will increase from 6.4 to 8% in the
world population by the year 2030 making the incidence of DFUs
potentially even more common (Nolan et al., 2011).
VLU and DFU Pathophysiology Overview
VLUs are characterised by venous hypertension, persistent
inflammation, hemosiderin deposition and lipodermatosclerosis
(Eming et al., 2014). This chronic inflammatory state suggests a
failure of VLUs to progress through the physiological pattern of
wound healing stages (Agren et al., 2000; Smith 2001; Wlaschek and
Scharffetter-Kochanek 2005). The hallmarks of DFUs are
hyperglycaemia, micro-/macroangiopathy, neuropathy and
infection, the condition usually culminating in foot deformities
(Eming et al., 2014). Similar to VLUs, diabetic wounds show an
unresolved inflammatory state, suggesting a hindrance of the
transition from the pro-inflammatory to the proliferative stage of
wound healing (Sibbald and Woo 2008).
Increased NOS Activity in Both VLUs and
DFUs
In chronic venous ulcer histological sections, the expression of
both eNOS and iNOS was increased when compared to normal
skin samples (Shimizu et al., 1997; Abd-El-Aleem et al., 2000).
This enhanced NOS expression correlated with an increase in
NOS activity, suggesting a higher NO production than that of
normal skin tissue (Abd-El-Aleem et al., 2000). In addition, a
venous stasis-dependent accumulation of NOS-expressing M1
macrophages is one of the prevalent features of VLUs (Rosner
et al., 1995; Abd-El-Aleem et al., 2000), with hypoxia and the low
shear stress contributing to the transmigration of such “trapped”
leukocytes into the tissue. Once there, they release high amounts
of ROS such as Fenton reaction-derived OH− (Yeoh-Ellerton and
Stacey 2003), proteolytic enzymes like MMP2 or MMP9
(Wysocki et al., 1993), and proinflammatory cytokines such as
TNFα, IL-1 and IL-6 (Tarnuzzer and Schultz 1996). These
contribute to extensive connective tissue breakdown and
subsequent ulcerations (Wlaschek and Scharffetter-Kochanek
2005). The large amounts of NO produced via iNOS activity
interact with the ROS resulting from the respiratory burst of the
macrophages/neutrophils present at the wound site, leading to
the formation of peroxynitrite (Beckman et al., 1990). Both NO
and peroxynitrite cause apoptotic cell death, thus contributing to
the damage seen in chronic venous ulcers (Albina et al., 1993;
Messmer et al., 1994; Lin et al., 1995). Moreover, Sindrilaru et al.
have directly linked the persistent inflammation and ECM
breakdown of VLUs with a perpetuated M1 proinflammatory
state of iron-overloaded macrophages, as iron chelation,
etanercept-dependent TNFα inhibition and clodronate-induced
macrophage depletion improve the phenotype of these ulcers
(Sindrilaru et al., 2011).
As far as diabetic ulcers are concerned, eNOS is increased at
the base and edge of the ulcer in DFUs when compared to normal
and diabetic human skin, thus showing similarities to the eNOS
TABLE 1 | Summary of key ARG pathway-related pathological commonalities between DFUs and VLUs. Although NOS and ARG are known to have competitive enzymatic
activities when expressed within the same cell, they both contribute to DFUs and VLUs, as they show discrete wound expression sites. iNOS is mainly present in
endothelial cells and macrophages present at the ulcer base, contributing to defective matrix deposition and necrosis via excessive NO. ARG is mainly expressed in the
dermal fibroblasts of the skin surrounding the ulcer itself. The increased ARG activity of both ulcer types is associated with fibrosis surrounding the ulcerations, resulting in
either calluses or lipodermatosclerosis in DFUs and VLUs respectively. The enhanced levels of the cytokine TGF-β noted in the sclerotic skin adjacent to the venous ulcer
further contributes to this excessive ARG activity.
Category Feature References
ARG activity and distribution Hyperactive ARG in the fibroblasts, macrophages and endothelial cells of surrounding dermis
leading to pathological fibrosis surrounding ARG-hindered ulceration
Herrick et al. (1992)
Jude et al. (1999)
Abd-El-Aleem et al. (2000)
NOS activity and distribution Upregulated e/iNOS activity in wound bed M1 pro-inflammatory macrophages leading to large
amounts of NO and subsequent necrosis/ulceration
Albina et al. (1993)
Messmer et al. (1994)
Lin et al. (1995)
Jude et al. (1999)
Inflammatory status Perpetuated M1 pro-inflammatory macrophages contributing to protracted inflammation via
TNFα, IL1 and IL6 within ulceration, and hindering transition to ARG-related proliferative stage
Sindrilaru et al. (2011)
Expression and distribution of proteolytic
enzymes
Excessive wound bed ECM breakdown due to abnormal levels of macrophage/neutrophil MMP2
and MMP9 overriding ARG-dependent ECM deposition
Herrick et al. (1997)
ROS and tissue oxidative stress Excessive ROS-dependent DNA damage causing fibroblast senescence within wound bed and
impairing ECM deposition, despite enhanced ARG activity
di Fagagna et al. (2003)
Garinis et al. (2009)
Growth factors High levels of ARG-inducing TGF-β in sclerotic skin adjacent to ulcer, but drastically reduced within
ulcer per se
Higley et al. (1995)
Boutard et al. (1995)
Stevens et al. (1997)
Angiopathies Perivascular cuffs and reduced compliance associated to proliferative and matrix deposition
effects of excessive ARG activity
Hagenfeldt et al. (1989)
Pieper and Dondlinger
(1997)
Kovamees et al. (2016)
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expression seen in VLUs (Table 1). In addition, an increased
iNOS expression was noted at the ulcer margins, predominantly
localised to the smooth muscle cells of the blood vessels as well as
the infiltrated macrophages (Jude et al., 1999). The similarity
between this iNOS localisation and that seen in VLUs provides a
further commonality between these two ulcer types (Table 1). As
well as expression of eNOS and iNOS, there is an increased total
NOS activity in DFUs, when compared to normal and diabetic
skin and the NOS is thought to be largely macrophage derived
(Jude et al., 1999). Similar findings have been reported in rodent
models (Stevens et al., 1997). Upregulated catalytic activity in
DFU patients was also mirrored by increased plasma NO2 levels,
and treatment with insulin lowered NO2 concentration in these
sufferers (Stevens et al., 1997; Jude et al., 1999). The excessive
levels of nitrite may provide a likely explanation for the DFU-
associated neuropathies. The increased NOS activity of ulcers was
further corroborated in a recent study by Dixit et al. conducted in
61 patients with chronic wound cases, DFUs and VLUs being the
most predominant lesions. By comparing the tissue and serum
enzyme activities at initial patient presentation and 12-weeks
follow-ups, an increased expression and activity of NOS was
noted at the second time point (Dixit et al., 2021). Thus, this
further highlights the putative metabolic implications of the NOS
isoforms in chronic wound healing.
Increased ARG Activity in Both VLUs and
DFUs
Perhaps surprisingly given the high levels of NOS, VLUs show
increased ARG activity concentrated in fibroblast- and
macrophage-like cells present in both the epidermis and the
dermis surrounding the wound bed (Abd-El-Aleem et al.,
2000; Sindrilaru et al. 2011). However, these macrophages fail
to fully switch from a pro-inflammatoryM1 state to a tissue repair
M2 one and transiently co-express high levels of M1 associated
markers such as TNFα and C-C chemokine receptor type 2
(CCR2) as well as intermediate levels of M2 markers like
ARG, CD36 and CD206 (Sindrilaru et al., 2011).
Despite the upregulation of ARG in chronic venous ulcers, the
matrix deposition was defective. The upregulation of certain
proteases like Ser proteases and neutrophil elastases might
explain this discrepancy, as their excessive proteolytic activity
leads to the breakdown of fibronectin within the wound bed
(Herrick et al., 1997). The lack of a fibronectin scaffold for
fibroblast integrin-dependent migration hinders their matrix
deposition capabilities. In addition, the enhanced release of
ROS, especially OH− and peroxynitrite, by the macrophage
population described by Sindrilaru et al. is a likely contributor
to this defective matrix deposition. The extensive ROS-related
DNA damage (Szabo et al., 2007) triggers a senescent program in
skin resident fibroblasts (di Fagagna et al., 2003; Garinis et al.,
2009), thus impairing their tissue repair capabilities (Sindrilaru
et al., 2011). Higher ARG levels may, therefore, be explained, in
part, as a consequence of a failed compensatory mechanism for
the extensive wound bed tissue breakdown.
Akin to VLUs, ARG expression is high in dermal fibroblasts
and endothelial cells (Jude et al., 1999, Table 1). This ARG
upregulation was shown to be involved in the pathological
fibrosis seen in the callus that surrounds the DFU (Jude et al.,
1999) and has also been described in rodent studies (Kampfer
et al., 2003; Miao et al., 2012). Similarly, significantly increased
ARG has been reported in chronic skin wounds 12 weeks after
initial presentation (Dixit et al., 2021). It is not fully known why
these defective transitions occur in ulcers but one factor may be
due to a lack of critical cytokines such as TGFβ1 in the wound
environment.
Lack of TGFβ as an Ulceration-Related
Factor
When compared to both normal and diabetic skin, macrophage
TGFβ1 expression in DFUs is drastically reduced or even absent
(Stevens et al., 1997; Jude et al., 1999). Given that TGFβ increases
the ARG activity at the expense of NOS activity (Boutard et al.,
1995), this lack of TGFβ1 in the ulcer macrophages translates into
an impaired transition from the tissue debridement to the tissue
repair stage. This provides a possible reason for the NO-rich
necrotic area characteristic of DFUs (Ferguson et al., 1996), a
raised and sustained NOS activity being deleterious. Moreover,
the diabetes-specific hyperglycaemic environment impairs the
normal phenotypic transition of wound macrophages as well as
their iNOS/ARG activity with compromised responses to their
instructive cytokines being noted (Gordon 2003; Gordon and
Taylor 2005; Miao et al., 2012). However, much remains to be
learnt about factors involved in driving macrophage polarisation
with the chronic wound bed.
Systemic Complications of Excessive Ulcer
ARG1 Activity
The high levels of ARG1 noted in several cell types present within
and around the granulation tissue of both VLU and DFUs,
including fibroblasts, macrophages, endothelial and vascular
smooth muscle cells, might contribute to systemic
complications as well. A polyamine-driven hyperplasia or
hypertrophy of blood vessels may lead to the underlying
venous hypertension characteristic of VLU patients. What is
more, the ARG1-triggered excessive collagen deposition
further contributes to this hypertensive phenotype, due to the
thickening and stiffening of blood vessels (Table 1). These blood
vessel architecture-related assumptions are corroborated by
studies showing that coronary arteries isolated from diabetes
patients had increased ARG1 expression and exhibited an
impaired endothelium-dependent vasorelaxation (Bagi et al.,
2013). Furthermore, other studies highlighted a correlation
between increased ARG activity, decreased plasma L-arginine
levels and endothelial dysfunction in type 2 diabetic patients and
diabetic rats, reinforcing the idea of ARG-dependent pathological
vascular remodelling, fibrosis and decreased compliance in DFUs
(Table 1) (Hagenfeldt et al., 1989; Pieper and Dondlinger 1997;
Kovamees et al., 2016). However, this hyperactive ARG does not
help with tissue deposition and repair within the wound per se.
This section emphasises the possible implications of ARG in
ulcers at both local and systemic levels while highlighting the
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similarities between DFUs and VLUs. This suggests that there
might be a certain molecular common ground between these two
ulcer types which would be worth exploiting when it comes to
therapeutical options. Indeed studies have highlighted the
etiological commonalities between different ulcerations (Chen
and Rogers 2007).
In addition to the putative implications of ARG in conditions
like ulcers, its activity is also associated with the balance micro-
organismal populations residing on the skin. Skin infection in
chronic wounds is a major risk factor in poor healing. Therefore,
the next section studies the implications of ARG in the context of
chronic infected wounds.
ARG AND THE SKIN MICROBIOTA
Themicrobial composition of wounds also play an important role in
the healing process and alterations in skin bacterial communities
have been associated with VLUs and DFUs, among other skin
conditions (Hannigan and Grice 2013; Weyrich et al., 2015). ARG
activity has been linked to the presence of certain pathogens within
the wound microenvironment, further suggesting the far-reaching
implications of this enzyme in wound healing (Debats et al., 2006).
This section will explore the changes seen in wound-related
microbiota, as opposed to normal skin microorganisms, and how
these impact on the activity of the ARG pathway and vice versa.
Homeostatic and Wound-Related Skin
Microbiota
The skin is heavily populated by bacteria, viruses, archaea and
fungi, all contributing to the holobiont. There is a constant
crosstalk between the skin microorganism and the host as
changes in the microbial communities populating the skin can
trigger the expression of antimicrobial peptides and
inflammatory molecules (Zeeuwen et al., 2012). Even in the
absence of overt signs of infection, the impairment seen in
certain chronic wounds has been associated with the presence
of a specific bioburden consisting of bacteria belonging to the
Staphylococcus, Pseudomonas, Peptoniphilus, Enterobacter,
Stenotrophomonas, Finegoldia, and Serratia genera (Gardner
et al., 2013; Eming et al., 2014; Misic et al., 2014; Rahim et al.,
2017). These polymicrobial communities exist mainly in the form
of tightly packed aggregates with synergistic virulence known as
biofilms (James et al., 2008). The biofilm composition differs from
that of normal skin, the latter consisting mainly of resident flora
such as S. epidermidis or Propionibacterium, and transient flora
such as S. aureus or Proteus mirabilis, different body parts having
varying micro-organismal proportions or abundances (Rahim
et al., 2017).
Hallmarks of Infected Chronic Wounds and
Impact on L-arginine Metabolism
According to a comparative study between patients displaying
acute, chronic non-infected and chronic infected wounds, acute
wounds have considerably lower indicators of inflammation and
a lack of infection signs, with no bacteria cultured from their
wound fluid (Debats et al., 2006) whereas infected chronic
wounds are often associated with Pseudomonas aeruginosa,
Staphylococcus aureus, Escherichia coli, and Proteus mirabillis
(Debats et al., 2006). Considerably decreased levels of plasma
L-arginine were noted in patients with infected chronic wounds,
when compared with both acute and non-infected chronic wound
patients (Debats et al., 2006). Despite decreased plasma
L-arginine, no differences in systemic inflammatory markers
such as Erythrocyte Sedimentation Rate (ESR) and albumin
were noted when infected chronic wounds were compared
with their non-infected counterparts (Debats et al., 2006)
indicative of a local rather than a systemic response.
Therefore, this suggests an increased uptake and metabolism
of L-arginine at the site of chronic infected lesions, the infection
being the likely driver of this increased metabolic activity.
However, it should be pointed out that both ESR and albumin
are crude, non-specific markers of systemic inflammation, certain
endogenous pyrogens, such as IL-6 and TNFα, representing
better options.
Wound fluid L-citrulline, L-ornithine and ARG1 levels are
significantly increased in infected chronic wounds, when
compared to non-infected wounds and normal skin (Debats
et al., 2006). These increased levels of certain AA at the
wound site may be explained by an extensive proteolysis.
However, L-ornithine is a non-proteinogenic AA and, hence,
it is not incorporated into polypeptide chains during protein
biosynthesis. Therefore, it is unlikely that L-ornithine is released
by proteolysis. This seems to suggests that the increase in wound
fluid L-ornithine is the likely consequence of an increased ARG1
activity (Debats et al., 2006). Although the synthesis and
breakdown of L-ornithine are important for producing wound
healing-related metabolites (Figure 1) (Bachrach et al., 2001;
Urdiales et al., 2001), these excessive L-ornithine levels
paradoxically contribute to wound chronicity rather than
accelerated wound closure.
Significantly decreased levels of the NOmetabolites nitrite and
nitrate were noted in infected chronic wounds, while their plasma
levels were similar to that of acute and non-infected chronic
lesions (Debats et al., 2006). This, together with enhanced ARG
levels, strongly suggests that the NOS activity within the chronic
infected wound is reduced. However, the increase in wound
citrulline production then seems paradoxical. An explanation
for the unexpected increase in citrulline is provided by the
presence of Arginine Deiminase (ADI)-expressing bacteria like
P. aeruginosa and E. coli. This enzyme can catalyse the direct
conversion of L-arginine into citrulline (Galkin et al., 2004;
Debats et al., 2006). Indeed, when cultured in the fluid derived
from infected wounds, these bacteria use L-arginine in order to
generate energy in the form of ATP (Theil et al., 1969; Lu et al.,
1999), therefore the inherent bacterial catalytic ability may
account for overall increased wound citrulline. Moreover, the
decreased production of bactericidal NO may further contribute
to defective barrier function in infected wounds where
microorganism growth is not being hindered by a NO-rich
microenvironment. This seems to suggest that the excessive
ARG activity may contribute to bacterial growth and thus
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impaired wound healing of infected lesions. However,
macrophage ARG1 activity has been shown to play a central
role in restricting bacterial growth and restraining tissue damage
in hypoxic tuberculosis granulomas (Duque-Correa et al., 2014),
suggesting that the relationship between ARG activity and
bacterial burden might be tissue- and pathology-specific.
In light of what has been said, the presence of an infection is a
likely contributor to the hindered progression of the wound
healing process and it is notable that successful wound closure
is associated with a low microbial count (Edwards and Harding
2004). Nevertheless, it is worth saying that certain studies
emphasise the importance of bacterial colonisation, setting a
threshold of 104 Colony Forming Units (CFUs)/ml as a
delineation between colonisation and wound healing-impeding
infection (Trengove et al., 1996). Moreover, isolates from
different parts of the same wound house different organisms
(Schneider et al., 1983). Furthermore, the stability of the chronic
wound microbiota is important as successful healing is associated
with a flexible dynamic microbiota (Loesche et al., 2017).
Owing to the intricate interplay between molecular, cellular
and microbial components associated with impaired wound
healing, the difficulty of devising highly effective chronic
wound treatments becomes obvious. The following section
highlights some of the most common chronic wound
therapeutical approaches based on the modulation of the ARG
pathway.
ARG PATHWAY-BASED CHRONIC WOUND
TREATMENT OPTIONS
Given the far-reaching implications of the ARG pathway in
wound healing and pathology as well as the extensive web of
molecular components contributing to this pathway, the search
for its druggable targets seems to be a sensible step in the attempt
to design a multimodal treatment for chronic skin conditions.
While some treatments focus on the AAs of this pathway by
means of nutritional or parenteral supplementation, other
current monotherapies aim to target the enzymatic nodes of
the ARG pathway via pharmacological modulation. Both of these
approaches will be discussed in this section.
Nutritional Therapy
Nutritional factors have a crucial role in the development of
chronic wounds (Schaffer et al., 1997). Nutritional therapy
involving the intake of vitamins A and C (MacKay and Miller
2003) or proteins (Ruberg 1984; Breslow et al., 1993) in
malnourished patients with chronic wounds has led to an
improvement in wound healing, although complete wound
closure was not observed (Thomas 2001; Houwing et al.,
2003). A more targeted strategy proposes using the
supplementation of specific AAs known to be of great
importance in the wound healing cascade of events (Angele
et al., 2002; Witte et al., 2002; Shi et al., 2003) such as
L-arginine and L-Ornithine (Barbul et al., 1990; Albina et al.,
1993; Efron and Barbul 2000). Unfortunately, little is known
about the effects of the addition of exogenous L-arginine to
chronic wounds, as to date enteral L-arginine supplementation
was mainly studied in acute artificially induced wounds, in both
humans and rodents. Parenteral means of administration have
also been studied, intravenous, intraperitoneal, subcutaneous and
dressing-based topical applications of L-arginine being the most
common approaches. Both enteral and parenteral
supplementation contributed to increased collagen synthesis
and enhanced wound breaking strength (Stechmiller et al., 2005).
L-arginine supplementation has been associated with
enhanced production of NO at the chronic wound site (Norris
et al., 1995; Schaffer et al., 1996; Pollock et al., 2001) which may
then contribute to granulation tissue formation, immune
responsiveness and angiogenesis (Yamasaki et al., 1998;
Schaffer et al., 1999; Witte and Barbul, 2002). Furthermore,
L-arginine supplementation has been regarded as an adjunct
treatment for either normalising or enhancing wound healing,
since the body does not produce sufficient amounts of this AA
during metabolically-demanding times of stress (Albina et al.,
1988; Witte and Barbul 2003). Proper levels of L-ornithine are
crucial for the production of proline (Albina et al., 1993), an
essential AA for collagen synthesis (Morris 1992), and
polyamines, key players in cell growth and proliferation
(Dolynchuk et al., 1994; Wu and Morris 1998). L-ornithine
may also regulate the catalytic activity of ARG via a feedback
loop mechanism as high AA levels could be an inhibitor of ARG
activity (Hunter and Downs 1945). Dietary polyamines should
not be excluded as a treatment option either, as systemic
administration of spermidine led to accelerated skin wound
healing in a mouse excisional back wound model (Ito et al., 2021).
ARG-promoting treatments might also be worth considering.
A biomaterial-based controlled release of IL-4 prompted a switch
from M1 to ARG1-expressing M2 phenotype in RAW 264.7
macrophages, while the treatment of the same macrophage cell
line with Echinacea-derived alcohol extracts enhanced their ARG
activity (Zhai et al., 2009; Yang et al., 2018). These treatments,
even though restricted to macrophage alternative activation and
the enhancement of their ARG enzymatic activity, might prove to
have overarching anti-inflammatory implications in the overall
chronic wound healing outcome. However much remains to be
elucidated about arginase modulation or its downstream
metabolites supplementation in the healing response.
Pharmacological Antagonism of ARG
Activity
Pharmacological inhibitors of ARG or NOS represent other
therapeutic means intended for targeting the activity of ARG
itself. DFMO, a potent inhibitor of OCD, acts as a weak,
nonspecific inhibitor of ARG (Table 2) (Morris 2009). The
ARG inhibitory effect of the DFMO treatment can be
mediated by the accumulation of L-ornithine feedbacking on
ARG and limiting its activity (Hunter and Downs 1945; Caldwell
et al., 2018). The potent inhibition of OCD by DFMO would also
limit the polyamine production, this limitation preventing the
backward metabolism of spermidine/spermine by PAO
(Figure 1), therefore reducing the oxidative stress of the
wound site (Caldwell et al., 2018). Two potent
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pharmacological inhibitors of ARG are NOHA and its analogue
nor-NOHA which has a longer half-life (Table 2). However, the
shortcoming of NOHA is that it is an intermediate metabolite in
the NOS-mediated pathway of L-arginine breakdown (Caldwell
et al., 2018).
Competitive ARG inhibitors with high specificity have been
developed, their design being based on the determination of the
crystal structure of human ARG1/2 (Kanyo et al., 1996; Di
Costanzo et al., 2005). These highly selective ARG inhibitors
are S-(2-boronoethyl)-L-cysteine (BEC) and 2(S)-amino-6-
boronohexanoic acid (ABH) (Baggio et al., 1999) and their
strong competitive inhibition results from the binding of their
boronic heads to the Mn cluster found at the catalytic site of ARG
(Table 2) (Berkowitz et al., 2003). Despite their specificity for
ARG, the drawback of using these pharmacological inhibitors is
that they are not isoform-selective (Caldwell et al., 2018).
Furthermore, there may be unintended consequences of
blocking arginase indiscriminately as it expressed by so many
cell types in the skin. The proper design of isotype-selective, cell-
specific inhibitors may facilitate the future development of
strategies aimed at modulating the enzymatic activity of ARG
in order to restore its homeostatic activity in pathological
conditions.
Of the ARG inhibitors described in this section, nor-NOHA,
BEC and ABH are commercially available and have been used in
preclinical animal models as well as in humans with promising
results reported for the small-scale treatment of patients with
hypertension (Holowatz and Kenney 2007) and T2DM
(Shemyakin et al., 2012), however, there is no information
currently available on any clinical trials in patients with
chronic wounds.
Chronic wounds were also associated with a sustained
upregulation of iNOS (Abd El-Aleem et al., 2000). Therefore,
targeting this enzyme of the ARG pathways might also represent a
therapeutic option. Given the known homeostatic push-and-pull
mechanism between iNOS and ARG in the context of acute
wound healing, it would be expected that iNOS inhibition might
trigger the pro-healing activity of ARG. However, an in vivo study
of incisional skin wound healing in hairless but
immunocompetent SKH-1 female mice showed no difference
in wound tensile strength or histopathological features (such as
epidermal hyperplasia, fibrin deposition and oedema) upon iNOS
inhibition via SC-842 (Bell et al., 2007). Moreover, iNOS
inhibition by means of both selective (aminoguanidine; AG;
Table 2) and non-selective (N-Nitro-L-Arginine Methyl Ester;
L-NAME; Table 2) inhibitors delayed wound closure and
increased scarring in an in vivo acute incisional back wound
model involving adult male, Sprague Dawley rats (Abd El-Aleem
et al., 2020).
Natural Products with Wound Healing
Properties
In addition to conventional drug-based treatments to specifically
target ARG pathways, there is increasing interest in the use of
traditional medicines as adjunctive therapies for chronic skin
conditions (Kulprachakarn et al., 2017), and it is possible that
these will modulate ARG pathways. Further study and validation
are needed to understand the underlying mechanisms involved in
their restorative effects. Notably, enhanced wound healing has
been linked to the bioactive constituents of organic products such
as Achillea asiatica (Dorjsembe et al., 2017), Aloe vera (Daburkar
et al., 2014), catechins (Kapoor et al., 2004), grapefruit (Kandhare
et al., 2014), honey (Vijaya and Nishteswar 2012) and turmeric
(Ibrahim et al., 2018). The wound-healing related attributes of
these constitutes include antibacterial, anti-inflammatory,
antioxidant, and pro-collagen synthesis properties (Ibrahim
et al., 2018). Given these attributes are closely linked to the
TABLE 2 | Summary of key ARG-pathway related drug pharmacodynamics. The inhibitory mechanisms of ARG pathway-targeting drugs are given together with their
inhibition constants (Ki). * iNOS-specific range.
Drug Pharmacology Ki References
ABH commercially available for preclinical use; highly specific competitive ARG inhibitor; its boronic head binds to the
catalytic Mn(II) cluster of ARG
0.25 μM Baggio et al. (1999)
Colleluori and Ash (2001)
Berkowitz et al. (2003)
Caldwell et al. (2018)
AG selective irreversible inhibitor of cytokine-induced iNOS; L-arginine analogue competitive at substrate and gene
level
NA Salinas-Carmona et al.
(2020)
BEC commercially available for preclinical use; highly selective competitive ARG inhibitor; its boronic head binds to the
catalytic Mn(II) cluster of ARG
0.31 μM Baggio et al. (1999)
Colleluori and Ash (2001)
Berkowitz et al. (2003)
Caldwell et al. (2018)
DFMO weak indirect inhibitor of ARG via potent ODC inhibition and L-ornithine accumulation feedback 3.9 mM Selamnia et al. (1998)
Morris (2009)
L-NAME non-selective competitive reversible NOS inhibitor 4–65 μM * Rees et al. (1990)
Furfine et al. (1993)
NOHA potent competitive endogenous ARG inhibitor; L-arginine analogue binding the ARGMn(II) cluster; also acts as an
intermediate in NOS-dependent L-citrulline production, thus being a bisubstrate
10 μM Daghigh et al. (1994)
Custot et al. (1997)
Caldwell et al. (2018)
nor-
NOHA
commercially available for preclinical use; reversible selective ARG inhibitor; more potent than its longer NOHA
analogue; binds ARG Mn(II) cluster
0.5 μM Custot et al. (1997)
Caldwell et al. (2018)
SC-842 selective iNOS inhibitor; no further details found in literature NA Bell et al. (2007)
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effector functions of ARG, the possibility of their interaction with
members of the ARG pathways cannot be excluded. Indeed, in
vivo model studies of Aloe vera, grapefruit extracts
(Kulprachakarn et al., 2017) and the catechin epicatechin
galatte (ECG) (Kapoor et al., 2004) showed that there was
modulation of the ARG pathways. A significant upregulation
of iNOS activity was noted in the early stages of the wound
healing process (days 1–3), whilst a significant decrease in ARG1
activity was observed during the same time interval (Kapoor et al.,
2004). The applicability of natural compounds in clinical practice
has seen an improvement in recent years, due to being
incorporated into different formulations based on hydrogels,
micelles or nanoparticles (Ibrahim et al., 2018). These
formulations have helped overcome pharmacodynamic
problems such as poor aqueous solubility and fast degradation
rates, therefore enhancing medicine delivery and bioavailability
(Ibrahim et al., 2018; Kant et al., 2021). As more of these products
become more pharmacokinetically available, further work may
assess and target the molecular components of the ARG
pathways.
Even though several current options for the ARG-dependent
treatment of chronic wounds and their pitfalls have been
presented in this section, the fast-paced development of new
technologies as well as our ever-improving understanding of the
chronic wound aetiology should help us develop better preclinical
and patient-related procedures in the near future. In clinical
practice, chronic wound monotherapies have led to
unsatisfactory results. Thus, the need for the design of a
multimodal treatment for chronic skin conditions is imperative.
DISCUSSION, FUTURE OPTIONS AND
PERSPECTIVES
The activity of ARG may be modulated by intrinsic differences in
human skin. ARG activity in the context of wound healing may
vary depending on the sex, age and demographics of the patients
(Wong et al., 2016). Sex-related differences are important, as skin
is thinner in women than men (Sandby-Møller et al., 2003) which
is further exacerbated during the menopause due to depletion of
oestrogen (Chen et al., 2001). Age differences between patients
should also be taken into consideration, as the diminished
elasticity, xerosis and immunosenescence noted in aging skin
can have a considerable impact on the outcome of studies
involving the ARG pathway (Leyden 1990).
In patients with chronic wounds, underlying systemic factors
such as advanced age, compromised immunological status and
constant mechanical stress can contribute to poor healing, as is
the case of the ulcers described in this review. Due to the need to
target both systemic comorbidities, like diabetes or hypoperfusion,
and local/regional skin impairments, Eming et al. raise the question
of possible drug-drug interactions in patients with chronic wounds.
Therefore, the best treatment approach would be to normalise the
underlying systemic condition while administering local treatment,
paying close attention to the pharmacodynamics of the multiple
drugs used (Eming et al., 2014). In addition, given that the chronic
wound aetiology is multifactorial, a synergising multimodal
treatment targeting several growth factors, ECM components and
cell types, rather than the ARG pathway alone, may improve the
quality of future treatments (Eming et al., 2014). As far as prospective
clinical trials are concerned, their large-scale successfulness may
depend on the improvement of inclusion criteria, proper patient
stratification and standardisation. These factors may also facilitate
the implementation and interpretation of future meta-analyses.
While ulcers highlight the likely implications of a
malfunctioning ARG pathway in macrophages and fibroblasts,
the pathological activity of ARG in other wound healing-related
cells known to express this enzyme should not be neglected either.
Due to inappropriate re-epithelialisation, the aetiology of chronic
skin conditions has been strongly linked to keratinocytes.
However, little attention has been given to the implications of
ARG-expressing epidermal cells in the context of chronic
wounds. Since the downstream metabolites of the ARG
pathway (especially the polyamines) have been extensively
associated with cell proliferation and differentiation, the links
between the ARG pathway, the polyamines and inappropriate re-
epithelialisation might be worth highlighting in the context of
chronic wounds. Therefore, this represents a future research
avenue that may improve our understanding of ARG in the
context of non-healing wounds.
CONCLUSION
To sum up, the ARG pathway is important in wound healing with
multiple roles as discrete points of the healing cascade. Defects in
arginase signalling, expression and/or function are common in
delayed healing wounds. However, more must be known about its
cell specific roles and how different morbidities and factors such
as age and sex impact it. Indeed, the translational potential of
emerging therapies aiming to fill the bench-to-bedside gap in
delivering arginase linked therapies will likely depend on a better
understanding of patient heterogeneity and stratification criteria.
Nevertheless, manipulation of the arginase pathway is an exciting
and important area to consider targeting to enhance healing and
improve patient outcomes.
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